Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Emery

Showing results (121-130 of 140) with videos related to

Pageof 14
Sort By:
Plos One|February 28, 2015
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
The Journal of Infectious Diseases|January 22, 2011
Plasma levels of soluble CD14 independently predict mortality in HIV infectionNetanya G Sandler, Handan Wand, Annelys Roque, et al.
Journal of the American Heart Association|May 24, 2017
Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) TrialJason V Baker, Shweta Sharma, Amit C Achhra, et al.
The Lancet. HIV|November 6, 2016
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE studyMark A Boyd, Janaki Amin, Patrick W G Mallon, et al.
HIV Clinical Trials|April 30, 2004
A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individualsSarah L Pett, Lisa A Williams, Richard O Day, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 28, 2017
Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected CohortsVijaya Madhavi, Archana Kulkarni, Ashwini Shete, et al.
AIDS (London, England)|November 26, 2019
Impact of early antiretroviral treatment on sexual behaviour: a randomised comparisonFiona C Lampe, Alison J Rodger, William Burman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 25, 2008
Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort dataBart Winters, Julio Montaner, P Richard Harrigan, et al.
Open Forum Infectious Diseases|December 13, 2016
Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) TrialJason V Baker, Katherine Huppler Hullsiek, Nicole Wyman Engen, et al.
Vaccine|November 9, 2004
Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12C Jane Dale, Robert De Rose, Kim M Wilson, et al.
Pageof 14

Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
Plos One|February 28, 2015
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
The Journal of Infectious Diseases|January 22, 2011
Plasma levels of soluble CD14 independently predict mortality in HIV infectionNetanya G Sandler, Handan Wand, Annelys Roque, et al.
Journal of the American Heart Association|May 24, 2017
Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) TrialJason V Baker, Shweta Sharma, Amit C Achhra, et al.
The Lancet. HIV|November 6, 2016
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE studyMark A Boyd, Janaki Amin, Patrick W G Mallon, et al.
HIV Clinical Trials|April 30, 2004
A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individualsSarah L Pett, Lisa A Williams, Richard O Day, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 28, 2017
Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected CohortsVijaya Madhavi, Archana Kulkarni, Ashwini Shete, et al.
AIDS (London, England)|November 26, 2019
Impact of early antiretroviral treatment on sexual behaviour: a randomised comparisonFiona C Lampe, Alison J Rodger, William Burman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 25, 2008
Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort dataBart Winters, Julio Montaner, P Richard Harrigan, et al.
Open Forum Infectious Diseases|December 13, 2016
Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) TrialJason V Baker, Katherine Huppler Hullsiek, Nicole Wyman Engen, et al.
Vaccine|November 9, 2004
Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12C Jane Dale, Robert De Rose, Kim M Wilson, et al.
Pageof 14